title: In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
abstract: BACKGROUND
  Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients.
  
  
  METHODS
  Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures.
  
  
  RESULTS
  Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.
  
  
  CONCLUSIONS
  Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration.
authors.affiliation: Faculty of Chemistry, National & Kapodistrian University of Athens, Panepistimioupolis Zografou, 15771 Athens, Greece. papakonstantinou.v@gmail.com.
authors.forename: Vasiliki D
authors.initials: VD
authors.lastname: Papakonstantinou
authors.forename: Maria
authors.initials: M
authors.lastname: Chini
authors.forename: Nikos
authors.initials: N
authors.lastname: Mangafas
authors.forename: George M
authors.initials: GM
authors.lastname: Stamatakis
authors.forename: Nickolaos
authors.initials: N
authors.lastname: Tsogas
authors.forename: Alexandros B
authors.initials: AB
authors.lastname: Tsoupras
authors.forename: Katherina
authors.initials: K
authors.lastname: Psarra
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fragopoulou
authors.forename: Smaragdi
authors.initials: S
authors.lastname: Antonopoulou
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Gargalianos
authors.forename: Constantinos A
authors.initials: CA
authors.lastname: Demopoulos
authors.forename: Marios-C
authors.initials: MC
authors.lastname: Lazanas
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000480:Alkynes; D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines / Q000627:therapeutic use; D003521:Cyclopropanes; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use; D010972:Platelet Activating Factor / Q000378:metabolism; D000068698:Tenofovir; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015850:Interleukin-6; D016209:Interleukin-8; D063065:Organophosphonates; D010972:Platelet Activating Factor; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; C098320:efavirenz